Buscar
Artiva Biotherapeutics Inc
ARTVAñadir a la lista de seguimiento
7.490USD
-0.230-2.98%
Cierre 09-24 16:00（ET）
363.94MCap. mercado
PérdidaP/E TTM
Acerca de Artiva Biotherapeutics Inc Compañía
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Perfil de Artiva Biotherapeutics Inc
Símbolo de cotizaciónARTV
Nombre de la empresaArtiva Biotherapeutics Inc
Fecha de salida a bolsaJul 19, 2024
Director ejecutivoAslan (Fred)
Número de empleados89
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 19
Dirección5505 Morehouse Drive
CiudadSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92121
Teléfono18582674467
Sitio Webhttps://www.artivabio.com/
Símbolo de cotizaciónARTV
Fecha de salida a bolsaJul 19, 2024
Director ejecutivoAslan (Fred)
Ejecutivos de Artiva Biotherapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
492.52K
+14.15%
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
492.52K
+14.15%
Dr. Subhashis Banerjee, M.D.
Dr. Subhashis Banerjee, M.D.
Chief Medical Officer
Chief Medical Officer
170.95K
+16.91%
Dr. Subhashis Banerjee, M.D.
Dr. Subhashis Banerjee, M.D.
Chief Medical Officer
Chief Medical Officer
170.95K
+16.91%
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
148.23K
-2.09%
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
148.23K
-2.09%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-55.67%
Dr. Brian Daniels, M.D.
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer and Compliance Officer
Chief Operating Officer, Chief Legal Officer and Compliance Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
492.52K
+14.15%
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
492.52K
+14.15%
Dr. Subhashis Banerjee, M.D.
Dr. Subhashis Banerjee, M.D.
Chief Medical Officer
Chief Medical Officer
170.95K
+16.91%
Dr. Subhashis Banerjee, M.D.
Dr. Subhashis Banerjee, M.D.
Chief Medical Officer
Chief Medical Officer
170.95K
+16.91%
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
148.23K
-2.09%
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
148.23K
-2.09%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Artiva Biotherapeutics Inc?
Los cinco principales accionistas de Artiva Biotherapeutics Inc son: Dr. Fred Aslan, M.D.
¿Cuántas instituciones poseen acciones de Artiva Biotherapeutics Inc (ARTV)?
A fecha de 2026Q1, 123 instituciones poseen acciones de Artiva Biotherapeutics Inc, con un valor de mercado combinado de aproximadamente 17.01M, lo que representa el 68.82% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -4519850.00.